AU2001242749A1 - Peptide derivative - Google Patents
Peptide derivativeInfo
- Publication number
- AU2001242749A1 AU2001242749A1 AU2001242749A AU4274901A AU2001242749A1 AU 2001242749 A1 AU2001242749 A1 AU 2001242749A1 AU 2001242749 A AU2001242749 A AU 2001242749A AU 4274901 A AU4274901 A AU 4274901A AU 2001242749 A1 AU2001242749 A1 AU 2001242749A1
- Authority
- AU
- Australia
- Prior art keywords
- function regulator
- regulator
- development
- present
- peptide derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
Abstract
The present invention relates to novel peptide derivatives, which are recognized as ligands to G-coupled protein receptor proteins. The peptide of the present invention can be used in (1) development of a receptor binding assay system using the expression system of the recombinant receptor protein and screening of candidates for pharmaceutical compounds, and (2) development of pharmaceutical preparations such as a neutral nerve function regulator, a circulatory function regulator, a cardiac function regulator, an immune function regulator, a digestive organ function regulator, a metabolic function regulator, a generative organ regulator or the like.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000087114 | 2000-03-23 | ||
JP2000-87114 | 2000-03-23 | ||
JP2000288891 | 2000-09-19 | ||
JP2000-288891 | 2000-09-19 | ||
PCT/JP2001/002278 WO2001070769A1 (en) | 2000-03-23 | 2001-03-22 | Peptide derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001242749A1 true AU2001242749A1 (en) | 2001-10-03 |
Family
ID=26588465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001242749A Abandoned AU2001242749A1 (en) | 2000-03-23 | 2001-03-22 | Peptide derivative |
Country Status (10)
Country | Link |
---|---|
US (1) | US7635751B2 (en) |
EP (1) | EP1270585B1 (en) |
JP (1) | JP4786047B2 (en) |
KR (1) | KR20020081466A (en) |
CN (1) | CN1419563A (en) |
AT (1) | ATE326478T1 (en) |
AU (1) | AU2001242749A1 (en) |
CA (1) | CA2403447A1 (en) |
DE (1) | DE60119714T2 (en) |
WO (1) | WO2001070769A1 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003063892A1 (en) * | 2002-01-29 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Use of apelin |
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
EP1967210A4 (en) * | 2005-12-20 | 2009-11-11 | Takeda Pharmaceutical | Novel application of apelin |
RU2303454C1 (en) * | 2006-06-22 | 2007-07-27 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Preparation for normalizing female reproductive function and method for its obtaining |
EP1903052A3 (en) * | 2006-07-28 | 2008-04-02 | Faust Pharmaceuticals SA | APJ receptor ligands and uses thereof |
WO2013050441A1 (en) | 2011-10-05 | 2013-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation |
US9381229B2 (en) | 2011-11-28 | 2016-07-05 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Pharmaceutical composition for use in the treatment of dysfunction associated with aging |
AU2013208109A1 (en) * | 2012-01-09 | 2014-08-14 | Anchor Therapeutics, Inc. | APJ receptor compounds |
US8921307B2 (en) | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
UY35144A (en) | 2012-11-20 | 2014-06-30 | Novartis Ag | APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT |
EP2935311B1 (en) | 2012-12-20 | 2021-03-31 | Amgen Inc. | Apj receptor agonists and uses thereof |
TW201536814A (en) | 2013-07-25 | 2015-10-01 | Novartis Ag | Synthetic cyclic polypeptides for the treatment of heart failure |
UY35671A (en) | 2013-07-25 | 2015-02-27 | Novartis Ag | SYNTHETIC APELINE POLYPEPTIDE BIOCONJUGATES |
CN104436158A (en) * | 2013-09-22 | 2015-03-25 | 华中科技大学 | Application of Apelin-13 to treatment of diabetic nephropathy |
GB201407532D0 (en) * | 2014-04-29 | 2014-06-11 | Univ Ulster | Apelin analogues |
PE20171328A1 (en) | 2015-01-23 | 2017-09-12 | Novartis Ag | CONJUGATES OF FATTY ACIDS AND SYNTHETIC APELLIN WITH LONGER HALF-LIFE |
ES2805743T3 (en) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Method and pharmaceutical composition for use in the treatment of diabetes |
MY193818A (en) | 2015-05-20 | 2022-10-27 | Amgen Inc | Triazole agonists of the apj receptor |
ES2930077T3 (en) | 2016-02-15 | 2022-12-07 | Inst Nat Sante Rech Med | Apelin for use in the treatment of postoperative cognitive dysfunction |
EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
MA46824A (en) | 2016-11-16 | 2019-09-25 | Amgen Inc | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS APJ RECEPTOR AGONISTS |
EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
EP3704122B1 (en) | 2017-11-03 | 2021-09-01 | Amgen Inc. | Fused triazole agonists of the apj receptor |
WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0846762A3 (en) * | 1992-11-17 | 1998-09-23 | Icos Corporation | Novel V31 seven transmembrane receptors |
ATE383424T1 (en) * | 1997-12-24 | 2008-01-15 | Takeda Pharmaceutical | POLYPEPTIDES, THEIR PRODUCTION AND USE |
US6475718B2 (en) * | 1998-09-08 | 2002-11-05 | Schering Aktiengesellschaft | Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
AU5759399A (en) * | 1998-09-25 | 2000-04-17 | Takeda Chemical Industries Ltd. | Peptide derivative |
-
2001
- 2001-03-22 CA CA002403447A patent/CA2403447A1/en not_active Abandoned
- 2001-03-22 EP EP01915695A patent/EP1270585B1/en not_active Expired - Lifetime
- 2001-03-22 US US10/239,321 patent/US7635751B2/en not_active Expired - Fee Related
- 2001-03-22 CN CN01807077A patent/CN1419563A/en active Pending
- 2001-03-22 AU AU2001242749A patent/AU2001242749A1/en not_active Abandoned
- 2001-03-22 WO PCT/JP2001/002278 patent/WO2001070769A1/en active IP Right Grant
- 2001-03-22 DE DE60119714T patent/DE60119714T2/en not_active Expired - Lifetime
- 2001-03-22 AT AT01915695T patent/ATE326478T1/en not_active IP Right Cessation
- 2001-03-22 KR KR1020027012331A patent/KR20020081466A/en not_active Application Discontinuation
- 2001-03-23 JP JP2001084010A patent/JP4786047B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1419563A (en) | 2003-05-21 |
EP1270585A4 (en) | 2004-12-15 |
US7635751B2 (en) | 2009-12-22 |
JP4786047B2 (en) | 2011-10-05 |
JP2002167397A (en) | 2002-06-11 |
EP1270585A1 (en) | 2003-01-02 |
ATE326478T1 (en) | 2006-06-15 |
CA2403447A1 (en) | 2001-09-27 |
WO2001070769A1 (en) | 2001-09-27 |
DE60119714D1 (en) | 2006-06-22 |
EP1270585B1 (en) | 2006-05-17 |
DE60119714T2 (en) | 2006-09-07 |
KR20020081466A (en) | 2002-10-26 |
US20040116336A1 (en) | 2004-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001242749A1 (en) | Peptide derivative | |
WO2000034317A3 (en) | Method for reducing immunogenicity of proteins | |
AU4162400A (en) | Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii | |
NO961115D0 (en) | Human metabotropic glutamate receptor subtypes (HMR4, HMR6, HMR7) and related DNA compounds | |
DE69633175D1 (en) | MULTIMINE PROTEINS | |
DK1005540T3 (en) | IKK-beta proteins, nucleic acids and methods | |
AU5759399A (en) | Peptide derivative | |
AU1208497A (en) | Ligand polypeptides for the g-protein-coupled receptor protein, their production and use | |
WO2001064877A3 (en) | Human schizophrenia gene | |
PT877803E (en) | PROTEIN RECEPTOR OB AND COMPOSITIONS AND RELATED METHODS | |
DE68925275D1 (en) | ENDOTOXIN BINDING PROTEIN AND THEIR USE | |
AU7017494A (en) | Purified mammalian flt3 ligands and agonists and antagonists thereof | |
EP0638067A4 (en) | Novel propoxyphene derivatives and protein and polypeptide propoxyphene derivative conjugates and labels. | |
EP0716591A4 (en) | METHODS AND COMPOSITIONS FOR BINDING TAU AND MAP2c PROTEINS | |
AU6517400A (en) | 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof | |
EP0239311A3 (en) | Mutual separation of proteins | |
EP0635016A4 (en) | Benzodiazepine derivatives and protein and polypeptide conjugates thereof. | |
WO1999042127A3 (en) | Receptor derived peptides as modulators of receptor activity | |
AU2003270010A1 (en) | Transferrin fusion protein libraries | |
WO2001064876A3 (en) | Human schizophrenia gene | |
AU2001238064A1 (en) | 18477, a human protein kinase and uses therefor | |
DE69611037D1 (en) | METHADONE DERIVATIVES AND PROTEIN AND POLYPEPTIDE METHADONE CONJUGATES AND MARKED COMPOUNDS | |
WO2003014293A3 (en) | Novel polypeptide analogs and fusions and their methods of use | |
NO992531L (en) | Methods of producing recombinant protein | |
EP0926239A3 (en) | Beta-lipotropin and uses thereof |